Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

• Status: Unknown status
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic and increasing the risk for developing nonalcoholic fatty liver disease (NAFLD). The strong relationship between insulin resistance and NAFLD suggests that adding Vitamin D TO insulin sensitizing therapies such as Galvus (vitagliptin) might be beneficial in the prevention or improvement in NAFLD. Considering the close relationship between NAFLD and T2DM and lipid metabolism, we assume that adding vitamin D to Galvus, may be effective for NAFLD by improving lipid metabolism and by improving type 2 diabetes mellitus (T2DM).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziv Hospital
• Treatments: Ergocalciferols; Vildagliptin; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 18-65 years old

• Men and women with NAFLD per US

• Increased ALT level

• Hepatomegaly

• Liver biopsy within 2 years

Exclusion Criteria:

• Other liver diseases (HBV, HCV)

• Hepatocellular carcinoma

• Decompensated liver disease

• Use of steroids